WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke XCUBE wurde als Wortmarke am 25.02.2021 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1612922 |
| Registernummer | 018297929 |
| Länder | 
|
| Basismarke |
Nr. 018297929,
27. Februar 2021
|
| Anmeldedatum | 25. Februar 2021 |
| Ablaufdatum | 25. Februar 2031 |
Markeninhaber
Paul-Ehrlich-Strasse 15
72076 Tübingen
DE
72076 Tübingen
DE
Markenvertreter
Alstertor 21
20095 Hamburg
DE
Waren und Dienstleistungen
09
Bioinformatics software; graphical user interface software;
artificial intelligence and machine learning software for
genome analysis, developing personal treatment strategies
for patients with diagnosed cancer, analyzing, screening,
identifying, quantifying, and interpreting data in the field
of mass spectrometry and next-generation sequencing (NGS);
electronic databases for bioinformatic purposes;
next-generation sequencing (NGS) data processor;
bioinformatics data processor; computer software
35
Compilation of statistical data and models with respect to
cancer treatment and cancer diagnosis
42
Computer programming in the medical, pharmaceutical and
biotechnological field; database design; maintenance of
database software; programming of software for importing and
managing data; information technology [IT] consulting
services for the pharmaceutical and healthcare industries;
computer programming for data processing; providing
temporary use of online non-downloadable computer software;
conducting evaluations in the field of pharmaceuticals;
consulting services in the fields of biotechnology and
pharmaceutical research; pharmaceutical product development
and evaluation services; pharmaceutical research and
development; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; research and development of pharmaceuticals for the
treatment of cancer; technical research in the field of
pharmaceutical studies; development of platform technology,
namely, cancer immunotherapy platforms for manufacturing
therapeutics; conducting clinical trials in the field of
pharmaceuticals for the treatment and prevention of cancer;
providing scientific molecular and genomic information for
medical and clinical research, for the treatment of cancer
and other diseases and disorders and for individuals'
responses to drug treatments; research and development of
medicines and diagnostic agents for cancer treatment and
cancer diagnosis; providing scientific advice in the fields
of cancer biology, cancer treatment, pharmaceutical side
effects, genomics, cancer medicine and translational
medicine; providing scientific analysis in the field of
next-generation sequencing (NGS) with respect to the
analysis and interpretation of genomic data obtained from
cancer patients; providing an online, non-downloadable
computer software platform for purposes of storing and
providing information about an individual's cancer profile
and genomic changes to enable physicians and healthcare
professionals to optimize treatment in clinical practice;
research and development services in the field of
immunology
44
Medical and pharmaceutical consultancy services
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 18. Januar 2023 | 2023/4 Gaz | KR | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 06. Oktober 2022 | 2022/41 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 03. Oktober 2022 | 2022/42 Gaz | IL | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 22. Juli 2022 | 2022/31 Gaz | KR | Ablehnung |
| 16. Juni 2022 | 2022/25 Gaz | JP | Ablehnung |
| 27. April 2022 | 2022/17 Gaz | GB | Ablehnung |
| 15. März 2022 | 2022/11 Gaz | SG | Ablehnung |
| 17. Januar 2022 | 2022/29 Gaz | CN | Ablehnung |
| 09. Januar 2022 | 2022/3 Gaz | IL | Ablehnung |
| 08. November 2021 | 2021/45 Gaz | US | Ablehnung |
| 06. Oktober 2021 | 2021/41 Gaz | Korrektur | |
| 25. Februar 2021 | 2021/35 Gaz | EM | Eintragung |
ID: 141612922